News about "Bristol Myers Squibb"

OXB Signs Multi-Year Commercial Supply Deal with Bristol Myers Squibb

Oxford Biomedica will serve as the commercial manufacturer of lentiviral vectors for Bristol Myers Squibb’s CAR-T programmes under a new multi-year supply agreement, which includes a five-year initial term with an option to extend.

Bristol Myers Squibb | 05/02/2026 | By News Bureau |  110

Janux Therapeutics and Bristol Myers Squibb Enter Cancer Drug Deal Valued at Up to USD Eight Hundred Fifty Million

Janux Therapeutics has entered into a global collaboration and exclusive licensing agreement with Bristol Myers Squibb to develop a novel cancer therapy for solid tumours. The partnership is valued at up to USD eight hundred fifty million, including upfront payments and development, regulatory, and commercial milestones.

Bristol Myers Squibb | 23/01/2026 | By Darshana

Syngene Renews Long-Term Research Alliance with Bristol Myers Squibb Until 2035

Syngene International has extended its long-term research collaboration with Bristol Myers Squibb until 2035, expanding the partnership to cover integrated services across the drug development lifecycle, from discovery and translational sciences to manufacturing, clinical trials and commercialisation support.

Bristol Myers Squibb | 20/01/2026 | By News Bureau

SCRI and Bristol Myers Squibb Expand Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

SCRI and Bristol Myers Squibb have expanded their collaboration to accelerate patient enrollment and extend access to advanced cancer clinical trials. By leveraging a data-driven strategy, the partnership aims to bring innovative research opportunities to a broader range of communities.

Bristol Myers Squibb | 15/11/2025 | By Dineshwori |  112

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec has reported advancement in its preclinical neuroscience collaboration with Bristol Myers Squibb, securing a payment of USD 25 Million to support the continued development of jointly pursued therapeutic programmes.

Bristol Myers Squibb | 28/10/2025 | By Dineshwori |  169

SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025

Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.

Bristol Myers Squibb | 21/10/2025 | By Dineshwori |  218

Alembic Pharmaceuticals Gets USFDA Nod for Triamcinolone Acetonide Injection

The approved ANDA, Triamcinolone Acetonide Injection, is therapeutically equivalent to the Reference Listed Drug (RLD) product, Kenalog-40 Injectable Suspension, of Bristol-Myers Squibb company.

Bristol-Myers Squibb | 21/10/2025 | By Dineshwori |  224

Bristol Myers Squibb Acquires Orbital Therapeutics

The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.

Bristol Myers Squibb | 13/10/2025 | By Dineshwori |  205

Lupin Secures US FDA Approval for Lenalidomide Capsules

The approved Lenalidomide Capsules, bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at Lupin’s Pithampur site in India.

Bristol-Myers Squibb | 17/09/2025 | By Dineshwori |  262

Alkermes appoints Joshua Reed as CFO

The newly-appointed CFO at Alkermes, Joshua Reed, brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics.

Bristol Myers Squibb | 13/09/2025 | By Dineshwori |  110